Apellis Pharmaceuticals Inc (NASDAQ: APLS) kicked off on Monday, up 4.39% from the previous trading day, before settling in for the closing price of $33.93. Over the past 52 weeks, APLS has traded in a range of $24.34-$73.80.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
A company in the Healthcare sector has jumped its sales by 73.14% annually for the last half of the decade. While this was happening, its average annual earnings per share was recorded 62.28%. With a float of $101.45 million, this company’s outstanding shares have now reached $122.07 million.
In an organization with 706 employees, it is important to assess its efficiency. In terms of profitability, gross margin is 86.34%, operating margin of -31.23%, and the pretax margin is -34.65%.
Apellis Pharmaceuticals Inc (APLS) Insider and Institutional Ownership
Our next focus will be how large-scale investors are participating in this stock of the Biotechnology Industry. The insider ownership of Apellis Pharmaceuticals Inc is 18.44%, while institutional ownership is 92.78%. The most recent insider transaction that took place on Sep 16 ’24, was worth 1,340,597. In this transaction Director of this company sold 37,000 shares at a rate of $36.23, taking the stock ownership to the 100,000 shares. Before that another transaction happened on Sep 16 ’24, when Company’s VP/Chief Accounting Officer sold 192 for $36.21, making the entire transaction worth $6,952. This insider now owns 38,141 shares in total.
Apellis Pharmaceuticals Inc (APLS) Latest Financial update
In the latest quarterly report, which was put into the public domain on 9/30/2024, the organization reported -0.73 earnings per share (EPS), lower than consensus estimate (set at -0.7) by -0.03. Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.42 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 62.28% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 33.30% during the next five years compared to -13.70% drop over the previous five years of trading.
Apellis Pharmaceuticals Inc (NASDAQ: APLS) Trading Performance Indicators
Take a look at Apellis Pharmaceuticals Inc’s (APLS) current performance indicators. Last quarter, stock had a quick ratio of 3.73. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 6.16.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -2.04, a number that is poised to hit -0.37 in the next quarter and is forecasted to reach -0.81 in one year’s time.
Technical Analysis of Apellis Pharmaceuticals Inc (APLS)
Let’s dig in a bit further. During the last 5-days, its volume was 3.29 million. That was better than the volume of 1.94 million it reported in year-ago period. As of the previous 9 days, the stock’s Stochastic %D was 95.75%. Additionally, its Average True Range was 1.74.
During the past 100 days, Apellis Pharmaceuticals Inc’s (APLS) raw stochastic average was set at 61.11%, which indicates a significant decrease from 98.87% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 76.83% in the past 14 days, which was higher than the 56.36% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $28.74, while its 200-day Moving Average is $41.31. However, in the short run, Apellis Pharmaceuticals Inc’s stock first resistance to watch stands at $36.10. Second resistance stands at $36.78. The third major resistance level sits at $38.03. If the price goes on to break the first support level at $34.17, it is likely to go to the next support level at $32.92. The third support level lies at $32.24 if the price breaches the second support level.
Apellis Pharmaceuticals Inc (NASDAQ: APLS) Key Stats
The company with the Market Capitalisation of 4.41 billion has total of 124,393K Shares Outstanding. Its annual sales at the moment are 396,590 K in contrast with the sum of -528,630 K annual income. Company’s last quarter sales were recorded 196,830 K and last quarter income was -57,450 K.
